Functionality of a bicistronic construction containing HEXA and HEXB genes encoding β-hexosaminidase A for cell-mediated therapy of GM2 gangliosidoses.

Neural Regeneration Research
Alisa A ShaimardanovaAlbert A Rizvanov

Abstract

Tay-Sachs disease and Sandhoff disease are severe hereditary neurodegenerative disorders caused by a deficiency of β-hexosaminidase A (HexA) enzyme, which results in the accumulation of GM2 gangliosides in the nervous system cells. In this work, we analyzed the efficacy and safety of cell-mediated gene therapy for Sandhoff disease and Sandhoff disease using a bicistronic lentiviral vector encoding cDNA of HexA α- and β-subunit genes separated by the nucleotide sequence of a P2A peptide (HEXA-HEXB). The functionality of the bicistronic construct containing the HEXA-HEXB genetic cassette was analyzed in a culture of HEK293T cells and human umbilical cord blood mononuclear cells (hUCBMCs). Our results showed that the enzymatic activity of HexA in the conditioned medium harvested from genetically modified HEK293T-HEXA-HEXB and hUCBMCs-HEXA-HEXB was increased by 23 and 8 times, respectively, compared with the conditioned medium of native cells. Western blot analysis showed that hUCBMCs-HEXA-HEXB secreted both completely separated HEXA and HEXB proteins, and an uncleaved protein containing HEXA + HEXB linked by the P2A peptide. Intravenous injection of genetically modified hUCBMCs-HEXA-HEXB to laboratory Wistar rats was carried out, ...Continue Reading

References

Sep 27, 2000·Proceedings of the National Academy of Sciences of the United States of America·R WadaR L Proia
Feb 16, 2005·Expert Opinion on Biological Therapy·Ulrich Matzner, Volkmar Gieselmann
Jul 29, 2008·Journal of Neuroimmunology·Stephanos KyrkanidesJohn A Olschowka
Nov 19, 2010·Science Translational Medicine·Bernhard GentnerLuigi Naldini
Apr 14, 2011·Molecular Therapy : the Journal of the American Society of Gene Therapy·Kazuhiko MatsuokaKohji Itoh
Apr 27, 2011·Annals of Neurology·Daisuke TsujiKohji Itoh
Nov 26, 2011·Developmental Medicine and Child Neurology·Nicholas J SmithChristopher M Verity
Jan 24, 2012·Molecular Genetics and Metabolism·Maria Francisca CoutinhoSandra Alves
Jun 26, 2012·Immunological Reviews·Yukio Takeshita, Richard M Ransohoff
Oct 24, 2012·Molecular Therapy : the Journal of the American Society of Gene Therapy·Frank HarrisonStephanie Cherqui
Jun 12, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·Ana SergijenkoBrian W Bigger
Nov 6, 2014·Molecular Biotechnology·Wojciech BarczakKatarzyna Kulcenty
Jun 11, 2015·Molecular Therapy : the Journal of the American Society of Gene Therapy·Jonas DoerrPhilipp Koch
Nov 6, 2015·Scientific Reports·Yuancheng WangQingyou Xia
Jan 31, 2017·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Tina M CalderonJoan W Berman
May 10, 2017·Molecular Genetics and Metabolism·Jeanine R Jarnes UtzChester B Whitley
Sep 20, 2017·Human Gene Therapy·Heather L Gray-EdwardsDouglas R Martin
Dec 14, 2018·Frontiers in Physiology·Valeriya V SolovyevaAlbert A Rizvanov
Dec 12, 2018·Molecular Therapy. Methods & Clinical Development·Evan WoodleyJagdeep S Walia
Jun 19, 2019·Molecular Therapy : the Journal of the American Society of Gene Therapy·John MarshallSeng H Cheng
Nov 9, 2019·Pharmaceutics·Alisa A ShaimardanovaValeriya V Solovyeva
Nov 17, 2020·Frontiers in Medicine·Alisa A ShaimardanovaAlbert A Rizvanov

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphatics

The CNS contains lymphatic vessels in the meninges that connect and drain the CSF into the peripheral lymphatic system. Impaired functioning of the CNS lymphatic system can be dangerous with the accumulation of toxic substances such as amyloid protein that is part of Alzheimer’s disease pathogenesis. Here is the latest research on the CNS lymphatics.